Program
TYK-00540
A development code.
Its studies are mostly in Breast Neoplasms, led by TYK Medicines.
Furthest: phase 2, since Apr 11, 20253 company-led studies, 3 open or runningNext primary completion: Nov 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TYK Medicines | 33 open or running | phase 2since Apr 11, 2025 | Jan 18, 2024 | Nov 2026phase 2 · NCT07104643 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 18, 2024First study: phase 1 study in Locally Advanced or Metastatic Solid TumorsFirst studyNCT06246071 · 156 planned · China
- Apr 11, 2025Phase 2 study in HR-positive, HER2-negative Advanced Breast CancerNCT06950086 · 180 planned · China
- Jul 29, 2025Phase 2 study in mCRPCNCT07104643 · 48 planned · China
Ahead
- Nov 2026Primary completion: phase 2 study in mCRPCNCT07104643
- Dec 5, 2026Primary completion: phase 1 study in Locally Advanced or Metastatic Solid TumorsNCT06246071
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07104643mCRPC · China | 2 | Not yet recruiting | Nov 2026 | 48 |
| NCT06950086HR-positive, HER2-negative Advanced Breast Cancer · China | 2 | Recruiting | Sep 2026 | 180 |
| NCT06246071Locally Advanced or Metastatic Solid Tumors · China | 1 | Recruiting | Dec 5, 2026 | 156 |
How it is read
Names in the registry
- “TYK-00540”, 3 entries
Codes read as this program: TYK00540.
Conditions, from the studies’ own filings
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.